Wacker Chemie

A precipitous step deeper into the CDMO business

23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."

PDF page sample
Pages
55
Language
English
Published on
23/11/20
Download
You may also be interested by these reports :
23/07/26
Givaudan’s performance in the first half of the year was mixed. Revenue surpassed expectations, driven by strong results in the Fragrance & Beauty ...
23/07/26
Fuchs announced strong Q2 2026 preliminary results, driven by pre-buying and likely market share gains. The FY 2026 guidance is slightly positive. ...
22/07/26
Akzo’s Q2 2026 sales saw positive pricing more than offsetting volume and mix declines. Deco volumes remain subject to consumer confidence, ...
20/07/26
A closest peer is potentially going to be established in 4Q26

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO